Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim, triggering a payment of €1.0 million. Evotec transitioned a back-up compound from a respiratory program into preclinical development.   Dr. Mario Polywka, chief operating officer of Evotec, said, “We have now achieved twenty three milestones as part of the collaboration with Boehringer Ingelheim. The completed research phase of this alliance has led to significant potential clinical milestones and royalti...